Efficient and cell-specific delivery of DNA is essential for the effective and safe use of gene delivery technologies. Consequently, a large variety of technologies have been developed and applied in a wide range of ex vivo and in vivo applications, including multiple approaches based on viral vectors. However, widespread success of a technology is largely determined by the versatility of the method and the ease of use. The rationally designed adapter technology previously developed redirects widely used human adenovirus serotype 5 (HAdV-C5) to a defined cell population, by binding and blocking the adenoviral knob tropism while simultaneously allowing fusions of an N-terminal retargeting module. Here we expand modularity, and thus applicability of this adapter technology, by extending the nature of the cell-binding portion. We report successful receptor-specific transduction mediated by a retargeting module consisting of either a DARPin, a single-chain variable fragment (scFv) of an antibody, a peptide, or a small molecule ligand. Furthermore, we show that an adapter can be engineered to carry more than one specificity, allowing dual targeting. Specific HAdV-C5 retargeting was thus demonstrated to human epidermal growth factor receptor 2 (HER2), human folate receptor α, and neurotensin receptor 1, effective at vector concentrations as low as a multiplicity of infection of 2.5. Therefore, we report a modular design which allows plug-and-play combinations of different binding modules, leading to efficient and specific mono-or dual-targeting while circumventing tedious optimization procedures. This extends the technology to combinational applications of cell-specific binding, supporting research in gene therapy, synthetic biology, and biotechnology.G ene therapy is a fast-growing field of biomedical research, recently exceeding more than 4000 ongoing or completed clinical trials. 1 This rapid progress became possible due to successes in numerous DNA delivery methods, including physical gene transfer, synthetic nanoparticles, and viral or cellular vectors. 2,3 Especially for in vivo applications, viral vectors have been shown to achieve high transduction rates and sustained expression. 4−6 Adenoviral vectors (AdVs) in particular are among the most frequently applied gene vectors, and they are currently being investigated for multiple clinical applications, including but not limited to the fields of vaccines, oncology, or rare diseases. 1,7−13 Among the more than 100 human adenovirus serotypes, the most prominent and best studied AdV serotype is the human adenovirus serotype C5 (HAdV-C5). 14,15